LEKSUM and SLU Partner to Pioneer Muscle Research in Unique ICU Lab
TL;DR
Leksum LLC's partnership with SLU establishes a unique muscle research lab, offering unparalleled insights into ICU-related muscle myopathies, positioning Leksum as a leader in advanced biologic therapies.
The lab utilizes a unique experimental ICU model to study long-term muscle mass and function loss, enabling detailed mechanistic and intervention studies under ICU conditions.
This collaboration aims to develop therapies for muscle myopathies, improving the quality of life for millions of ICU patients worldwide by addressing critical illness myopathy.
Leksum and SLU's groundbreaking lab can replicate long-term ICU conditions, a world-first, paving the way for innovative treatments in muscle myopathy research.
Found this article helpful?
Share it with your network and spread the knowledge!
The partnership between LEKSUM LLC and the Swedish University of Agricultural Sciences (SLU) marks a significant advancement in muscle research, particularly in understanding and treating conditions arising from long-term ICU stays. The newly established lab, led by Lars Larsson, MD/PhD, is the only one of its kind capable of conducting long-term studies under ICU conditions without the limitation of early mortality, a common confounding factor in such research.
This collaboration is pivotal as it enables the study of critical illness myopathy (CIM) and other muscle myopathies over extended periods, mirroring the conditions of human ICU patients. The ability to maintain life support beyond the few days possible with standard ventilators allows for a more accurate replication of ICU conditions, facilitating both mechanistic and intervention studies. This research is crucial for developing therapies that can prevent or treat muscle myopathies in millions of patients worldwide, particularly those immobilized and on mechanical ventilation in ICUs.
Professor Larsson's enthusiasm for the partnership underscores its potential to revolutionize the approach to treating acquired muscle myopathies. The lab's unique capabilities not only fill a critical gap in current research methodologies but also pave the way for innovative therapies that could significantly improve patient outcomes in ICUs and beyond.
Curated from Reportable
